Qiagen (NYSE:QGEN) Stake Decreased by Martingale Asset Management L P

Martingale Asset Management L P lessened its holdings in shares of Qiagen (NYSE:QGEN) by 12.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 292,675 shares of the company’s stock after selling 40,073 shares during the period. Martingale Asset Management L P owned 0.13% of Qiagen worth $13,337,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in QGEN. PEAK6 Investments LLC raised its holdings in Qiagen by 270.0% during the first quarter. PEAK6 Investments LLC now owns 7,925 shares of the company’s stock worth $341,000 after purchasing an additional 12,587 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Qiagen by 13.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 91,763 shares of the company’s stock worth $3,945,000 after purchasing an additional 10,683 shares in the last quarter. CWM LLC raised its holdings in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares in the last quarter. SG Americas Securities LLC raised its holdings in Qiagen by 14.2% during the second quarter. SG Americas Securities LLC now owns 496,951 shares of the company’s stock worth $20,420,000 after purchasing an additional 61,815 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft raised its holdings in Qiagen by 88.0% during the second quarter. Baader Bank Aktiengesellschaft now owns 37,602 shares of the company’s stock worth $1,540,000 after purchasing an additional 17,602 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Up 1.2 %

NYSE QGEN opened at $43.75 on Friday. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The stock has a market cap of $9.98 billion, a price-to-earnings ratio of 112.18, a PEG ratio of 3.39 and a beta of 0.41. The firm’s 50 day moving average price is $43.25 and its two-hundred day moving average price is $43.73.

Wall Street Analyst Weigh In

QGEN has been the topic of several recent analyst reports. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Qiagen presently has an average rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.